Gilead expands access to investigational obeldesivir for Ebola Bundibugyo through voluntary licensing
GILD•Gilead signed royalty-free voluntary licensing agreements for investigational obeldesivir as post-exposure prophylaxis for Ebola Bundibugyo virus disease, covering 127 low- and lower-middle-income countries. The agreements include all African countries with Ebola Bundibugyo cases and expand remdesivir licensing to filovirus disease.
1. Licensing agreements
Gilead signed royalty-free voluntary licensing agreements for investigational obeldesivir as post-exposure prophylaxis for Ebola Bundibugyo virus disease. The agreements cover 127 low- and lower-middle-income countries, including all African countries with Ebola Bundibugyo cases; Dr. Reddy’s, Eva Pharma and Ferozsons Laboratories entered into agreements with Gilead.
2. Remdesivir access
Gilead also expanded its voluntary licensing agreements for remdesivir to include filovirus disease.




